Chronic hepatitis B
Conditions
Interventions
Group 1:Tenofovir alafenamide was administered at the 28th week of pregnancy and discontinued immediately after delivery.
Group 2:Tenofovir alafenamide was administered at the 28th week of pregnancy and discontinued one month after delivery.
Group 3:Tenofovir alafenamide was administered at the 28th week of pregnancy and discontinued three month after delivery.
Sponsors
The First Affiliated Hospital of Zhengzhou University
Eligibility
Sex/Gender
Female
Age
20 Years to 40 Years
Inclusion criteria
Inclusion criteria: 1. Pregnant womon; 2. Aged 20-40 years; 3. Diagnosed with HBeAg positive chronic hepatitis B virus infection.
Exclusion criteria
Exclusion criteria: 1. Comorbided with cirrhosis and/or hepatocellular carcinoma; 2. Coinfected with other hepatotropic virus (such as hepatitis C virus, et al);comorbided with alcoholic liver diseases,fatty liver diseses, autoimmune liver hepatitis, drug-induced liver injury and genetic liver diseases; 3. Comorbided with systemic disorders (such as hypertension,diabetes and human immunodeficiency virus infection, et al); 4. Comorbided with psychiatric disorders and psychological diseases.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety of tenofovir alafenamide for mothers and infants;Successful rate of prevention for mother-to-child transmission of hepatitis B virus;Withdrawal time of tenofovir alafenamide; | — |
Countries
China
Contacts
Public ContactQinglei Zeng
The First Affiliated Hospital of Zhengzhou University
Outcome results
None listed